2WV2

X-ray structure of CYP51 from the human pathogen Trypanosoma brucei in complex with fluconazole

• PDB DOI: https://doi.org/10.2210/pdb2WV2/pdb

• Classification: OXIDOREDUCTASE
• Organism(s): Trypanosoma brucei
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2009-10-12 Released: 2009-11-10 
• Deposition Author(s): Chen, C.-K., Leung, S.S.F., Guilbert, C., Jacobson, M., McKerrow, J.H., Podust, L.M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.70 Å
• R-Value Free: 0.274 
• R-Value Work: 0.210 
• R-Value Observed: 0.213 

Literature

Structural Characterization of Cyp51 from Trypanosoma Cruzi and Trypanosoma Brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole

Chen, C.-K., Leung, S.S.F., Guilbert, C., Jacobson, M., Mckerrow, J.H., Podust, L.M.

(2010) PLoS Negl Trop Dis 4: E651

• PubMed: 20386598 
• DOI: https://doi.org/10.1371/journal.pntd.0000651
• Primary Citation of Related Structures:  
  2WUZ, 2WV2, 2WX2, 2X2N


• PubMed Abstract: 
  

  Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other major global pathogens, Leishmania spp., responsible for leishmaniasis, and Trypansoma brucei, the causative agent of African Sleeping Sickness. Both T. cruzi and Leishmania parasites have an essential requirement for ergosterol, and are thus vulnerable to inhibitors of sterol 14alpha-demethylase (CYP51), which catalyzes the conversion of lanosterol to ergosterol. Clinically employed anti-fungal azoles inhibit ergosterol biosynthesis in fungi, and specific azoles are also effective against both Trypanosoma and Leishmania parasites. However, modification of azoles to enhance efficacy and circumvent potential drug resistance has been problematic for both parasitic and fungal infections due to the lack of structural insights into drug binding.

---

Organizational Affiliation: 

Department of Pharmaceutical Chemistry, University of California, San Francisco, California, United States of America.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 54.9 kDa 
• Atom Count: 3,508 
• Modelled Residue Count: 443 
• Deposited Residue Count: 475 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
LANOSTEROL 14-ALPHA-DEMETHYLASE	A	475	Trypanosoma brucei	Mutation(s): 0  EC: 1.14.13.70
UniProt
Find proteins for Q385E8 (Trypanosoma brucei brucei (strain 927/4 GUTat10.1)) Explore Q385E8  Go to UniProtKB:  Q385E8

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
HEM	C [auth A]	PROTOPORPHYRIN IX CONTAINING FE C34 H32 Fe N4 O4 KABFMIBPWCXCRK-RGGAHWMASA-L
TPF	B [auth A]	2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL C13 H12 F2 N6 O RFHAOTPXVQNOHP-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
TPF	BindingDB:  2WV2	Kd: min: 230, max: 340 (nM) from 2 assay(s)
		IC50: 880 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.70 Å
• R-Value Free: 0.274 
• R-Value Work: 0.210 
• R-Value Observed: 0.213 
• Space Group: P 3₁ 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 106.179	α = 90
b = 106.179	β = 90
c = 99.73	γ = 120

Software Package:

Software Name	Purpose
REFMAC	refinement
MOSFLM	data reduction
SCALA	data scaling
ELVES	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2009-11-10 
Deposition Author(s): Chen, C.-K., Leung, S.S.F., Guilbert, C., Jacobson, M., McKerrow, J.H., Podust, L.M.

Revision History  

• Version 1.0: 2009-11-10
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Advisory, Version format compliance
• Version 1.2: 2012-05-30
  Changes: Other